TMCnet News

Altimmune to Participate at Two Upcoming Investor Conferences
[May 31, 2023]

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • Jefferies Healthcare Conference in New York, NY
    Friday, June 9, 2023
    Fireside chat at 8:30 am Eastern Time
  • Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA
    Wednesday, June 14, 2023
    Fireside chat at 4:00 pm Pacific Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmun website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
[email protected]

Primary Logo

[ Back To's Homepage ]